Panbela Therapeutics illékonyság
Mi az Panbela Therapeutics illékonyság?
A illékonyság az Panbela Therapeutics Inc. - 26.66%
Mi a illékonyság meghatározása?
A volatilitás vagy az átlagos valódi tartomány százalék (ATRP 14) a záróár százalékában kifejezve.
Average true range percent (ATRP) measures volatility on a relative level. This is opposed to the ATR, which measures volatility on an absolute level. ATRP allows securities to be compared whereas ATR does not. That means lower-priced stocks won't necessarily have lower ATR values than higher-priced stocks.
The period used in the calculation is 14 days and the normalized indicator oscillates between 0 and 100 percent of recent price variation. Importantly, the indicator doesn't predict the direction of price but it describes the current volatility. The volatility is comparable across all securities and all markets.
Volatility expresses the degree of price movement. The use of ATRP as volatility compared to ATR is preferred in cases when different securities or different time periods are compared. Examples are stock screening, filtering strategies, and studying seasonality and volatility patterns over long periods of time and different markets
illékonyság a Health Care szektor a NASDAQ-on cégekben a Panbela Therapeutics -hoz képest
Mit csinál Panbela Therapeutics?
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
illékonyság -hoz hasonló cégek Panbela Therapeutics
- Dubber nak illékonyság 26.50% van
- Riversgold nak illékonyság 26.55% van
- Kore Potash plc nak illékonyság 26.55% van
- Technology Minerals Plc Ord Gbp nak illékonyság 26.58% van
- Redx Pharma Plc nak illékonyság 26.59% van
- Great Eastern nak illékonyság 26.64% van
- Panbela Therapeutics nak illékonyság 26.66% van
- Peruvian Metals nak illékonyság 26.68% van
- West Wits Mining nak illékonyság 26.68% van
- Emmerson PLC nak illékonyság 26.70% van
- CTT Pharmaceutical nak illékonyság 26.74% van
- UBS ETF - MSCI USA Socially Responsible UCITS ETF nak illékonyság 26.76% van
- Panthera Resources PLC nak illékonyság 26.80% van